Alert detail
LCD L39427: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis — CGS
What changed
New MolDX policy affects biomarker testing reimbursement.
Who’s affected: Rheumatology billing teams · Effective: August 7, 2025
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 6 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.